Back to Journals » Therapeutics and Clinical Risk Management » Volume 4 » Issue 2

New approaches to managing asthma: a US perspective

Authors William E Berger

Published 11 April 2008 Volume 2008:4(2) Pages 363—379

DOI https://doi.org/10.2147/TCRM.S1382

William E Berger

Allergy and Asthma Associates of Southern California, Mission Viejo, CA, USA

Abstract: Despite remarkable advances in diagnosis and long-term management, asthma remains a serious public health concern. Newly updated expert guidelines emphasize the intra- and inter-individual variability of asthma and highlight the importance of periodic assessment of asthma control. These guidelines update recommendations for step-wise asthma treatment, address the burgeoning field of asthma diagnostics, and stress the importance of a patient and health care professional partnership, including written action plans and self monitoring. The field of asthma therapeutics is expanding rapidly, with promising new treatment options available or in development that may address some of the existing barriers to successful asthma management. These approaches simplify treatment, use combinations of agents in one delivery device that have complementary actions, or target specific pathways involved in asthma pathophysiology. Considerable activity is taking place in asthma pharmacogenetics. This review provides an overview of these new approaches to managing asthma, including their present status and future potential.

Keywords: asthma treatment, inhaled corticosteroids, long-acting β2-adrenergic agonists, guidelines, pharmacogenetics

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 

 

Readers of this article also read:

NK cell count as predictor of clinical response in patients with rheumatoid arthritis treated with rituximab

Lurati A, Bertani L, Marrazza M, Re KA, Bompane D, Scarpellini M

Biologics: Targets and Therapy 2012, 6:83-87

Published Date: 11 April 2012

Equitable access to HCV care in HIV-HCV co-infection can be achieved despite barriers to health care provision

Curtis L Cooper, Celine Giordano, Dave Mackie, et al

Therapeutics and Clinical Risk Management 2010, 6:207-212

Published Date: 20 April 2010

Intravitreal bevacizumab (Avastin) in the treatment of macular edema secondary to retinal vein occlusion

Juan Carlos Mesa Gutiérrez, Luis Arias Barquet, Josep Maria Caminal Mitjana, Sergi Prades Almolda, Nùria Planas Domènech, et al

Clinical Ophthalmology 2008, 2:787-791

Published Date: 5 December 2008

Bowen’s disease – a review of newer treatment options

Thorsten Neubert, Percy Lehmann

Therapeutics and Clinical Risk Management 2008, 4:1085-1095

Published Date: 10 October 2008

Preparation and biomedical application of a nonpolymer coated superparamagnetic nanoparticle

Lin Du, Jianzhao Chen, Yanting Qi, Dan Li, Chonggang Yuan

International Journal of Nanomedicine 2007, 2:805-812

Published Date: 15 January 2008

A critical analysis of barriers to the clinical implementation of pharmacogenomics

Ross A McKinnon, Michael B Ward, Michael J Sorich

Therapeutics and Clinical Risk Management 2007, 3:751-759

Published Date: 15 November 2007